There are published reports on the use of anti-IL12/23 (ustekinumab) for psoriasis and IBD with good response to treatment and no complications.38, 39 Regarding anti-IL17, there are two reports of patients with psoriasis who received ixekizumab, with good psoriasis control and without complications.40 Here, IL17A is linked to psoriasis.